Goodwin + KPMG 7th Annual Symposium @ JP Morgan Healthcare Conference 2026

Goodwin and KPMG hosted our 7th Annual Symposium on January 14, 2026, during the 44th Annual J.P. Morgan Healthcare Conference week.
In today’s market, M&A and strategic transactions are increasingly critical to sustaining innovation and fueling growth for life sciences and healthcare companies. This year’s symposium spotlighted how industry leaders leverage dealmaking — not just as a response to capital constraints, but as a catalyst to advance pipelines, strengthen balance sheets, and position for long-term success.
See you at the next one!
Featured Insights
To Monetize or Not to Monetize? The Question Late-Stage Life Sciences Companies Should Be Asking
Royalty monetization deals have become important financing alternatives for late-stage life sciences companies. What should companies be asking when it comes to their fundraising initiatives?

The New Playbook for Competitive Life Sciences M&A — How Buyers Can Differentiate Beyond Price Through Structure and Strategy
As competition in life sciences M&A grows, the playbook on how to win deals is being rewritten. Discover emerging tactics and considerations to position yourself as the best buyer.

Top 10 Issues in Cross-Border Life Sciences Transactions

Life Sciences Capital Markets: Preparing for Your 2026 IPO
With an upswing in IPO activity, take advantage of these considerations when planning your capital markets strategy for your upcoming IPO.

Symposium Videos
2026 Agenda
Learn More about Life Sciences and Healthcare at Goodwin
Life Sciences Practice
Our Life Sciences practice is uniquely positioned to partner with innovators and investors operating in a fast-moving, technology-driven environment. We work with life sciences companies throughout the corporate lifecycle, as well as with investors, banks, and others in the life sciences ecosystem.

Life Sciences Perspectives Blog
Our Life Sciences Perspectives blog is a resource specifically aimed at addressing your most frequent and pressing issues in this dynamic industry. We provide the insights you need most, including developments on private and public company matters, licensing deals and collaborations, patent and IP matters, FDA and healthcare regulatory compliance, and European and Asian developments for life sciences companies.

Integrated Healthcare Practice

Health Headlines










